CN115872950B - Fluorescent compound, application thereof in detection of urease and in-vitro diagnostic reagent - Google Patents
Fluorescent compound, application thereof in detection of urease and in-vitro diagnostic reagent Download PDFInfo
- Publication number
- CN115872950B CN115872950B CN202111125919.XA CN202111125919A CN115872950B CN 115872950 B CN115872950 B CN 115872950B CN 202111125919 A CN202111125919 A CN 202111125919A CN 115872950 B CN115872950 B CN 115872950B
- Authority
- CN
- China
- Prior art keywords
- urease
- fluorescent compound
- detection
- fluorescent
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010046334 Urease Proteins 0.000 title claims abstract description 56
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 27
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 9
- 238000000338 in vitro Methods 0.000 title claims description 5
- 238000001514 detection method Methods 0.000 title abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 9
- 239000000758 substrate Substances 0.000 claims abstract description 9
- 230000008859 change Effects 0.000 claims abstract description 7
- 230000007062 hydrolysis Effects 0.000 claims abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 238000010791 quenching Methods 0.000 abstract description 6
- 230000000171 quenching effect Effects 0.000 abstract description 6
- 239000012295 chemical reaction liquid Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 4
- 229940037467 helicobacter pylori Drugs 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 229950003937 tolonium Drugs 0.000 description 4
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 241000588770 Proteus mirabilis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- -1 carbonyldiimino Chemical group 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 244000088401 Pyrus pyrifolia Species 0.000 description 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960002143 fluorescein Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A fluorescent compound has a structure shown in the structural formula I, wherein R 1 And R is 2 Independently selected from a fluorescent group or a quenching group. When the substrate is contacted with the urease, the reaction liquid generates fluorescence characteristics under the hydrolysis of the urease, and the activity of the urease can be detected by measuring the change of the fluorescence intensity value. The urease detection efficiency and reliability are improved, and the detection time is shortened.
Description
Technical Field
The invention relates to a compound with fluorescence characteristics, in particular to a compound with a similar structure with urea, which is used as a substrate of urease, is used for detecting the content of the urease by utilizing the fluorescence characteristics of the compound, and is applied to medical equipment for detecting the urease.
Background
Urease is a nickel-containing metal oligoenzyme capable of hydrolyzing urea to produce carbon dioxide and ammonia, and widely exists in plant seeds, animal urine and blood, and many microorganisms can synthesize and secrete urease. Such as streptococcus salivarius, helicobacter pylori, actinomyces endometricus and other microorganisms parasitic in the upper digestive tract of human body can produce urease, and the urease produced by these microorganisms is related to pathogenicity, and common related diseases include dental caries, periodontitis, atrophic gastritis, peptic ulcer and the like. Compared with other urease-producing microorganisms, the helicobacter pylori has large urease content and high activity, the urease content of the helicobacter pylori accounts for 5% -10% of the total protein of cells, the urease activity of the helicobacter pylori is 2 times of that of the proteus mirabilis, and the intestinal bacteria is 7 times of that of the proteus mirabilis. Therefore, the urease activity determination can be used as a rapid diagnosis basis for helicobacter pylori infection in clinic.
The urease detection method mainly comprises a phenol red indicator method, a Nahner reagent chromogenic method, a latex agglutination test method, an immunoblotting and enzyme-linked immunosorbent assay. The principle of the above detection method can be divided into two types, one is that the color change of the indicator phenol red or Nashi reagent occurs based on ammonia generated by hydrolysis of substrate urea by urease; the other is an immune reaction that utilizes urease antibodies to specifically recognize urease antigens. These detection and analysis methods have some drawbacks such as: the method through antigen-antibody binding reaction has better specificity, but the detection time is longer, and the method using the pH value change of the reaction system has more severe requirements on the reaction conditions. Therefore, the development of a more efficient, simple, convenient, rapid and reliable urease detection method has important social significance.
Disclosure of Invention
The invention aims to provide a fluorescent compound which has a molecular structure similar to urea, takes the fluorescent compound as a substrate of urease, and utilizes the fluorescent characteristic of the compound under the hydrolysis of the urease to generate specific wavelength so as to realize qualitative or quantitative detection of the urease.
Another object of the present invention is to provide a method for preparing a fluorescent compound, which has a molecular structure similar to urea, and uses the molecular structure as a substrate for qualitative and quantitative detection of urease.
It is a further object of the present invention to provide a fluorescent compound for use in the detection of urease which results in a more efficient, simple and reliable urease detection.
It is a further object of the present invention to provide the use of a fluorescent compound in the manufacture of a medical device for detecting urease, such that the urease detection is more efficient, simpler and more reliable.
A fifth object of the present invention is to provide the use of a fluorescent compound for the manufacture of an in vitro diagnostic reagent for the detection of urease.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a fluorescent compound having a structure represented by the following structural formula I,
wherein R is 1 And R is 2 Independently selected from a fluorescent group or a quenching group. Such as: r is R 1 And R is 2 Selected from the same fluorescent groups; the other steps are as follows: r is R 1 Selected from fluorescent groups, R 2 Selected from quenching groups; another example is: r is R 1 Selected from the group consisting of quenching groups, R 2 Selected from fluorescent groups; another example is: r is R 1 And R is 2 Selected from the group of fluorophores, but the two groups have different excitation wavelengths, and the emission wavelength of one of the fluorophores is within the excitation wavelength range of the other fluorophore.
Fluorescent compounds of the invention, fluorescent groups such as: but are not limited to toluidine blue, coumarin, or fluorescein.
Fluorescent compounds of the invention, quenching groups such as: but are not limited to black hole quenchers (Black Hole Quencher, BHQ).
When the fluorescent compound is not contacted with urease, fluorescence is inhibited by a mechanism of fluorescence energy resonance transfer (fluorescence resonance energy transfer, FRET). When the reaction solution is a substrate and contacts with urease, under the hydrolysis action of the urease, the reaction solution generates fluorescence, generates fluorescence or enhances the fluorescence, and the activity of the urease can be detected by measuring the change of the fluorescence intensity value, such as: qualitative or quantitative detection.
Compared with the prior art, the detection principle for detecting urease is different. The invention directly calculates the urease by detecting the change of the fluorescence quantity of the urease hydrolysate, and the detection is quick and simple. In the prior art, urease activity is indirectly calculated by measuring the pH value change of a solution after urease reaction, or the detection is slow and complex by antigen-antibody combination detection analysis with harsh reaction conditions and slow time.
The fluorescent compound of the invention is used as a substrate to prepare urease medical devices, such as: and in-vitro diagnostic reagent to realize rapid quantitative and qualitative detection of urease.
A method for preparing the fluorescent compound provided by the invention comprises the following steps:
mixing urea containing two reaction functional groups with fluorescent molecules (such as toluidine blue) serving as a reaction raw material in a molar ratio of 1:2, dissolving the mixture in an organic solvent (such as triethylamine and dimethylformamide), and reacting at room temperature under a dark condition; after the reaction, the solvent was removed to obtain a solid, which was redissolved in methanol. Purifying by chromatography with methanol and dichloromethane at a volume ratio of 20:1 to obtain fluorescent compound.
Another method for preparing the fluorescent compound provided by the invention comprises the following steps:
mixing urea containing two reaction functional groups with fluorescent molecules (such as toluidine blue) and quenching molecules (such as BHQ 3) serving as reaction raw materials in a molar ratio of 1:1:1, dissolving in an organic solvent, and reacting at room temperature under a dark condition; after the reaction, the solvent was removed to obtain a solid, which was redissolved in methanol. Purifying by chromatography with methanol and dichloromethane at a volume ratio of 20:1 to obtain fluorescent compound.
Another method for preparing the fluorescent compound provided by the invention comprises the following steps:
with urea containing two reactive functional groups, with two different fluorescent molecules, such as: coumarin and fluorescein are mixed according to the mol ratio of 1:1:1 as reaction raw materials, dissolved in an organic solvent and reacted at room temperature under the condition of avoiding light; after the reaction, the solvent was removed to obtain a solid, which was redissolved in methanol. Purifying by chromatography with methanol and dichloromethane at a volume ratio of 20:1 to obtain fluorescent compound.
Drawings
FIG. 1 is a scheme showing the synthesis of fluorescent compounds in example 1 of the present invention;
FIG. 2 shows the nuclear magnetic resonance hydrogen spectrum 1H NMR of a fluorescent compound of example 1 of the present invention;
FIG. 3 is a linear relationship between urease concentration and amount of fluorescence measured by the fluorescent compound of example 1 of the present invention.
Detailed Description
The technical scheme of the present invention is described in detail below. The embodiments of the present invention are only for illustrating the technical scheme of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications and equivalents may be made thereto without departing from the spirit and scope of the technical scheme of the present invention, which is intended to be covered by the scope of the claims of the present invention.
In the examples below, all temperatures are in degrees Celsius (C.) unless otherwise indicated. Unless otherwise indicated, various starting materials and reagents are commercially available, such as Sigma-Aldrich, sammer feier technology (ThermoFisher Scientific). The starting materials and reagents obtained were used without further purification.
The glassware is oven dried and/or heat dried. The reaction was followed on a glass silica gel-60F 254 plate (0.25 mm) (TLC). Analytical thin layer chromatography and development was performed in the appropriate solvent ratio (v/v).
1 The H NMR spectrum was determined with a Bruker instrument (400 MHz) and the chemical shifts were expressed in ppm. Tetramethylsilane internal standard (0.00 ppm) was used. 1 H NMR representation method: s=singlet, d=doublet, t=triplet, m=multiplet, br=broadened, dd=doublet of doublet. If coupling constants are provided, they are in Hz.
The molecular weight of the product is determined by an LC/MS mass spectrometer, and the ionization mode is ESI or APCI.
The preparation methods provided by the present invention should be understood as examples given for the necessity of full disclosure and not as limitations on the scope of protection as claimed. The person skilled in the art will be able to prepare the various compounds provided by the invention according to the textbook, the laboratory manual or the guidance of the examples listed in the present invention. The preparation of these compounds is also within the ordinary skill of one of ordinary skill in the art and can be accomplished under the guidance of the prior art. Specifically, the preparation method of part of the compounds provided by the invention is shown in the following figure 1.
4,4'- (carbonyldiimino) bis-, 1' -bis (2, 5-dioxo-1-pyrrolidinyl) ester and toluidine blue are taken as reaction raw materials, and are mixed and dissolved in N, N-Dimethylformamide (DMF) solvent according to the mol ratio of 1:2, and triethylamine (triethylenediamine) is added for reaction at room temperature under the condition of light shielding; after the reaction, removing the solvent to obtain a black oily solid, dissolving the black oily solid in methanol, and further carrying out chromatographic purification by using methanol to dichloromethane 20:1 to obtain the fluorescent compound.
1H NMR (400 MHz, DMSO). Delta.10.13 (s, 1H), 9.90 (s, 1H), 8.59 (s, 1H), 8.31 (s, 1H), 8.15 (s, 1H), 7.93 (s, 1H), 7.27 (s, 2H), 7.14 (s, 1H), 6.91 (s, 2H), 6.65 (s, 2H), 3.58 (s, 8H), 3.17 (s, 2H), 3.10 (s, 2H), 3.04 (s, 2H), 2.97 (s, 3H), 2.89 (m, 1H), 2.73 (s, 1H), 2.58 (s, 6H), 2.24 (s, 2H), 2.10 (s, 2H), 1.98 (s, 2H), 1.56 (s, 4H), 1.23 (s, 2H), 0.95 (s, 2H) (FIG. 2). ES-MS (m/z): 838.23 (MH + )
The urease detection step comprises the following steps:
(1) Urease solutions with different concentrations were prepared with phosphate buffer at pH 7.4 to final concentrations of 0, 1.25, 2.5, 5, 10 and 20U/ml in 100. Mu.l assay system; adding a fluorescent compound with a final concentration of 5mmol/L into the urease solution, reacting for 3-5 minutes at 37 , measuring the fluorescence amount in the solution, and preparing a standard curve according to the urease concentration and the corresponding fluorescence amount, referring to fig. 3, so as to obtain a linear fitting equation y=1.029+0.078x.
(2) Adding a sample to be detected (such as saliva, gastric juice, urine, soil, gastric mucosa biopsy tissue sample and the like) into 100 mu L of a detection system, adding a fluorescent compound with a final concentration of 5mmol/L, reacting for 3-5 minutes at 37 , measuring the fluorescence amount in the solution, and calculating the urease enzyme activity in the sample according to a standard curve. Using a saliva sample as an example, the relative fluorescence was measured to be 1.411, and the urease activity was measured to be 1.68U/ml.
In the whole process, the detection can be completed in about 10 minutes, and compared with the prior art, the detection time is obviously shortened.
Claims (4)
1. A fluorescent compound characterized by having the structure shown below.
2. A method for detecting urease using the fluorescent compound of claim 1 as a substrate, wherein the reaction solution generates fluorescent characteristics under the hydrolysis of urease after the substrate is contacted with urease, and the activity of urease can be detected by measuring the change of the fluorescent intensity value.
3. The use of a fluorescent compound of claim 1 for the preparation of a medical device for detecting urease.
4. An in vitro diagnostic reagent for detecting the enzymatic activity of urease, characterized in that it comprises the fluorescent compound according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111125919.XA CN115872950B (en) | 2021-09-25 | 2021-09-25 | Fluorescent compound, application thereof in detection of urease and in-vitro diagnostic reagent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111125919.XA CN115872950B (en) | 2021-09-25 | 2021-09-25 | Fluorescent compound, application thereof in detection of urease and in-vitro diagnostic reagent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115872950A CN115872950A (en) | 2023-03-31 |
| CN115872950B true CN115872950B (en) | 2024-04-16 |
Family
ID=85762443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111125919.XA Active CN115872950B (en) | 2021-09-25 | 2021-09-25 | Fluorescent compound, application thereof in detection of urease and in-vitro diagnostic reagent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115872950B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072929A1 (en) * | 2003-10-28 | 2007-03-29 | Silva Antonio | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines |
| CN108135903A (en) * | 2015-09-09 | 2018-06-08 | 目标实验室有限责任公司 | NIR dyes targeting PSMA and their applications |
-
2021
- 2021-09-25 CN CN202111125919.XA patent/CN115872950B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070072929A1 (en) * | 2003-10-28 | 2007-03-29 | Silva Antonio | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines |
| CN108135903A (en) * | 2015-09-09 | 2018-06-08 | 目标实验室有限责任公司 | NIR dyes targeting PSMA and their applications |
Non-Patent Citations (4)
| Title |
|---|
| A Chemically Induced Vaccine Strategy for Prostate Cancer;Anna Dubrovska等;ACS Chem. Biol.(第6期);第1223–1231页 * |
| Development of Tumor-Targeted Near Infrared Probes for Fluorescence Guided Surgery;Lindsay E. Kelderhouse等;Bioconjugate Chem.;第24卷;第1075−1080页 * |
| Novel solid-phase strategy for the synthesis of ligand-targeted fluorescent-labelled chelating peptide conjugates as a theranostic tool for cancer;Sagnik Sengupta等;Beilstein J. Org. Chem.;第14卷;第2665–2679页 * |
| Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand;Sumith A. Kularatne等;MOLECULAR PHARMACEUTICS;第6卷(第3期);第780–789页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115872950A (en) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108484622B (en) | Synthesis of Multi-Signal Fluorescent Probes and Its Application in Simultaneous Differential Detection of Hcy, Cys and GSH | |
| CN106946902B (en) | A kind of sulfur dioxide near-infrared-two-photon ratio fluorescent probe and preparation method thereof | |
| US9533974B2 (en) | Ultra-sensitive chemiluminescent substrates for enzymes and their conjugates | |
| CN106279124B (en) | A kind of fluorescent probe for detecting tyrosinase and preparation method and application thereof | |
| JPH0137693B2 (en) | ||
| CN113045596B (en) | A kind of peroxynitroso anion and viscosity dual-responsive fluorescent probe and its preparation and application | |
| CN109928940B (en) | Preparation of near-infrared fluorescent probe molecule for detecting hypochlorous acid based on basic blue-3 | |
| CA2142867C (en) | Biotinylated chemiluminescent labels, conjugates, assays, assay kits | |
| CN113801105A (en) | Mitochondrion targeted peroxynitrite/bisulfite dual-response fluorescent probe | |
| CN116178414B (en) | Carboxylesterase fluorescent probe, preparation method and application thereof | |
| US4857455A (en) | Method for the determination of peroxidase using fluorogenic substrates | |
| CN114605343B (en) | Fluorescent group LAN-OH, fluorescent sensor LAN-beta gal, preparation method and application thereof | |
| CN115872950B (en) | Fluorescent compound, application thereof in detection of urease and in-vitro diagnostic reagent | |
| CA1174151A (en) | Method for the estimation of n-acylated primary aromatic amines | |
| CN111087362B (en) | Fluorescent probe for detecting formaldehyde with high selectivity, and synthetic method and application thereof | |
| CN115433181B (en) | Fluorescent probe based on hemicyanine structure, and preparation method and application thereof | |
| JPS62258390A (en) | Method for producing new phosphorylcholine derivatives | |
| CN112266358B (en) | Bifunctional fluorescent probe, preparation method and use | |
| CN112680216B (en) | Fluorescent probe for ammonia detection and preparation method and application of test paper thereof | |
| US6534637B2 (en) | Synthesis of chlorophenol red glucuronic acid | |
| CN115894537B (en) | High-selectivity hydrogen sulfide ratio fluorescent probe based on fluoroborodipyrrole dye and preparation and application thereof | |
| CN119409748A (en) | A chemiluminescent probe, kit and preparation method and application of N-acetyl-β-D-glucosamine enzyme | |
| CN110129033B (en) | Fluorescent probe for detecting butyrylcholinesterase activity and preparation method and application thereof | |
| CN120757468A (en) | Application of near infrared fluorescent probe of dicyanoisophorone derivative in preparation of bacillus anthracis detection product | |
| CN119118958A (en) | A near-infrared fluorescent probe for detecting hypochlorous acid and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |